Literature DB >> 18495795

Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension.

Steven D Crowley1, Campbell W Frey, Samantha K Gould, Robert Griffiths, Phillip Ruiz, James L Burchette, David N Howell, Natalia Makhanova, Ming Yan, Hyung-Suk Kim, Pierre-Louis Tharaux, Thomas M Coffman.   

Abstract

Activation of the renin-angiotensin system contributes to the progression of chronic kidney disease. Based on the known cellular effects of ANG II to promote inflammation, we posited that stimulation of lymphocyte responses by ANG II might contribute to the pathogenesis of hypertensive kidney injury. We therefore examined the effects of the immunosuppressive agent mycophenolate mofetil (MMF) on the course of hypertension and kidney disease induced by chronic infusion of ANG II in 129/SvEv mice. Although it had no effect on the severity of hypertension or cardiac hypertrophy, treatment with MMF significantly reduced albuminuria and ameliorated kidney injury, decreasing glomerulosclerosis and reducing lymphocyte infiltration into the renal interstitium. Attenuation of renal pathology with MMF was associated with reduced expression of mRNAs for the proinflammatory cytokines interferon-gamma and tumor necrosis factor-alpha and the profibrotic cytokine transforming growth factor-beta. As infiltration of the kidney by T lymphocytes was a prominent feature of ANG II-dependent renal injury, we carried out experiments examining the effects of ANG II on lymphocytes in vitro. We find that exposure of splenic lymphocytes to ANG II causes prominent rearrangements of the actin cytoskeleton. These actions require the activity of Rho kinase. Thus, ANG II exaggerates hypertensive kidney injury by stimulating lymphocyte responses. These proinflammatory actions of ANG II seem to have a proclivity for inducing kidney injury while having negligible actions in the pathogenesis of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18495795      PMCID: PMC2519187          DOI: 10.1152/ajprenal.00527.2007

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  62 in total

1.  Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor.

Authors:  G Wolf; F N Ziyadeh; F Thaiss; J Tomaszewski; R J Caron; U Wenzel; G Zahner; U Helmchen; R A Stahl
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Immunosuppressive treatment protects against angiotensin II-induced renal damage.

Authors:  Dominik N Muller; Erdenechimeg Shagdarsuren; Joon-Keun Park; Ralf Dechend; Eero Mervaala; Franziska Hampich; Anette Fiebeler; Xinsheng Ju; Piet Finckenberg; Jürgen Theuer; Christiane Viedt; Joerg Kreuzer; Harald Heidecke; Hermann Haller; Martin Zenke; Friedrich C Luft
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Tumor necrosis factor induces glomerular damage in the rabbit.

Authors:  T Bertani; M Abbate; C Zoja; D Corna; N Perico; P Ghezzi; G Remuzzi
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

4.  Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.

Authors:  D Balomenos; R Rumold; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

5.  Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Authors:  Giancarlo Viberti; Nigel M Wheeldon
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

6.  Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.

Authors:  Richard B Devereux; Björn Dahlöf; Eva Gerdts; Kurt Boman; Markku S Nieminen; Vasilios Papademetriou; Jens Rokkedal; Katherine E Harris; Jonathan M Edelman; Kristian Wachtell
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

7.  Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats.

Authors:  M Gómez-Chiarri; A Ortíz; J L Lerma; M J López-Armada; F Mampaso; E González; J Egido
Journal:  Lab Invest       Date:  1994-04       Impact factor: 5.662

8.  Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury.

Authors:  Jing Shao; Masaomi Nangaku; Toshio Miyata; Reiko Inagi; Koei Yamada; Kiyoshi Kurokawa; Toshiro Fujita
Journal:  Hypertension       Date:  2003-05-27       Impact factor: 10.190

9.  Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism.

Authors:  G Luvarà; M E Pueyo; M Philippe; C Mandet; F Savoie; D Henrion; J B Michel
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-09       Impact factor: 8.311

10.  Immunohistochemical detection of T-cell subsets and other leukocytes in paraffin-embedded rat and mouse tissues with monoclonal antibodies.

Authors:  J L Whiteland; S M Nicholls; C Shimeld; D L Easty; N A Williams; T J Hill
Journal:  J Histochem Cytochem       Date:  1995-03       Impact factor: 2.479

View more
  81 in total

1.  Hypertensive renal injury is associated with gene variation affecting immune signaling.

Authors:  Michael C Braun; Stacy M Herring; Nisha Gokul; Monique Monita; Rebecca Bell; Yaming Zhu; Manuel L Gonzalez-Garay; Scott E Wenderfer; Peter A Doris
Journal:  Circ Cardiovasc Genet       Date:  2014-11-03

2.  Renal injury in angiotensin II+L-NAME-induced hypertensive rats is independent of elevated blood pressure.

Authors:  Aaron J Polichnowski; Limin Lu; Allen W Cowley
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

Review 3.  CD4+CD25+Foxp3 regulatory T cells and vascular dysfunction in hypertension.

Authors:  Modar Kassan; Andrea Wecker; Philip Kadowitz; Mohamed Trebak; Khalid Matrougui
Journal:  J Hypertens       Date:  2013-10       Impact factor: 4.844

4.  Interferon-γ biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells.

Authors:  Ryousuke Satou; Kayoko Miyata; Romer A Gonzalez-Villalobos; Julie R Ingelfinger; L Gabriel Navar; Hiroyuki Kobori
Journal:  FASEB J       Date:  2012-02-01       Impact factor: 5.191

Review 5.  New insights into angiotensin receptor actions: from blood pressure to aging.

Authors:  Johannes Stegbauer; Thomas M Coffman
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-01       Impact factor: 2.894

6.  Epigallocatechin gallate inhibits angiotensin II-induced endothelial barrier dysfunction via inhibition of the p38 MAPK/HSP27 pathway.

Authors:  Dan Yang; Jing Liu; Cui Tian; Yong Zeng; Yue-hong Zheng; Quan Fang; Hui-hua Li
Journal:  Acta Pharmacol Sin       Date:  2010-07-19       Impact factor: 6.150

7.  A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension.

Authors:  Jian-dong Zhang; Mehul B Patel; Young-Soo Song; Robert Griffiths; James Burchette; Phillip Ruiz; Matthew A Sparks; Ming Yan; David N Howell; Jose A Gomez; Robert F Spurney; Thomas M Coffman; Steven D Crowley
Journal:  Circ Res       Date:  2012-04-24       Impact factor: 17.367

8.  Blood pressure control: salt gets under your skin.

Authors:  Paul J Marvar; Frank J Gordon; David G Harrison
Journal:  Nat Med       Date:  2009-05       Impact factor: 53.440

9.  The expression and functional evidence for voltage-dependent potassium channel Kv1.3 in lymphocytes during aging in spontaneously hypertensive rats.

Authors:  Ling-Peng Wang; Jian Luo; Hai-Feng Hu; Li Zhang; Ya-Li Li; Li-Man Ai; Yu-Ling Wang; Yi-Tong Ma; Hu-Yati Mu; Yue-Mei Hou
Journal:  Int J Clin Exp Med       Date:  2015-02-15

10.  Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice.

Authors:  Modar Kassan; Maria Galan; Megan Partyka; Mohamed Trebak; Khalid Matrougui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.